🇺🇸 FDA
Patent

US 9994856

Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein

granted A61KA61K31/7088A61K31/712

Quick answer

US patent 9994856 (Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein) held by ProQR Therapeutics II B.V. expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ProQR Therapeutics II B.V.
Grant date
Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7088, A61K31/712, A61K38/465, A61K45/06